Celadon Pharmaceuticals PLC Result of AGM
28 Juni 2024 - 8:00AM
RNS Regulatory News
RNS Number : 2526U
Celadon Pharmaceuticals PLC
28 June 2024
Celadon Pharmaceuticals
Plc
("Celadon" or the
"Company")
Result of Annual General
Meeting
London, UK, 28 June 2024:
Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical
company focused on the development, production and sale of
breakthrough cannabis-based medicines, announces that at its Annual
General Meeting held yesterday, all resolutions were duly
passed.
Full details of the poll results
have been set out on the Company's website.
Enquiries:
|
|
|
|
Celadon Pharmaceuticals Plc
|
|
|
James Short
Jonathan Turner
|
Via
Powerscourt
|
|
|
|
|
Canaccord Genuity Limited (Nominated Adviser and
Broker)
|
|
|
Bobbie Hilliam / Andrew
Potts
|
+44
(0)20 7523 8000
|
|
|
|
|
Global Investment Strategy UK Limited (Joint
Broker)
James
Sheehan
|
+44
(0)20 7048 9400
|
|
|
|
|
Powerscourt Group
|
|
|
Sarah MacLeod / Nick Johnson / Sam
Austrums
|
+44
(0)20 7250 1446
|
|
|
|
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK
based pharmaceutical company focused on the research, cultivation,
manufacturing, and sale of breakthrough cannabis-based medicines.
Its primary focus is on improving quality of life for chronic pain
sufferers, as well as exploring the potential of cannabis-based
medicines for other conditions such as autism. Its 100,000 sq. ft
UK facility is EU-GMP approved and comprises indoor hydroponic
cultivation, proprietary GMP extraction and manufacturing and an
analytical and R&D laboratory. Celadon's Home Office licence
allows for the commercial supply of its GMP pharmaceutical cannabis
product. The Group owns an approved clinical trial using cannabis
based medicinal products to treat chronic pain in the UK. Celadon
also has a minority interest in early-stage biopharma Kingdom
Therapeutics which is developing a licensed cannabinoid medicine to
treat children with Autism Spectrum Disorder.
For further information please visit
our website www.celadonpharma.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGQKOBNDBKBQAB
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
